Foresite Capital and OrbiMed Advisors led a $110m Series A round in RayThera.

Foresite Capital, a healthcare and life sciences investment firm, and OrbiMed Advisors, a global investment firm, led a $110m Series A round in RayThera, a biotechnology company, with participation from TTM Capital. “I’ve been impressed with the progress that the RayThera team has made in such a short time. Our ongoing collaboration with this skilled team exemplifies our commitment to back repeat entrepreneurs who have strong track records partnering with us,” Michael Rome, Foresite Capital Partner.